Freya Pharma Solutions, a pharmaceutical company specialising in innovative therapies for women diagnosed with Female Sexual Disorders (FSD), today announced it will rebrand as Arletta Pharma Solutions, effective immediately. The new name, derived from a rare butterfly species, symbolizes the company’s transformation as it progresses toward pivotal clinical milestones and its strategic objectives of securing regulatory approval.
The butterfly: A universal symbol in women’s healthcare
The name Arletta, inspired by a rare butterfly species, carries profound significance for women’s medical care. The butterfly symbolises transformation, change, beauty, and freedom-concepts that resonate deeply throughout women’s healthcare. Internationally, the term “butterfly” appears frequently in medical contexts related to women’s health, from anatomical structures to diagnostic indicators, reflecting the transformative nature of women’s life stages.
Clinical programmes advancing
Arletta Pharma’s Clitoral Doppler Duplex Ultrasonography (CDU) Phase II study is currently ongoing at Chaim Sheba Medical Center, evaluating two testosterone-sildenafil dose-combinations in 16 premenopausal women with acquired generalised FSIAD. Led by Professor Cobi Reisman and Dr Anna Padoa, the study utilises clitoral doppler duplex ultrasound imaging to quantify clitoral blood flow parameters, with preliminary data expected in the near term. Additionally, the company is finalising preparations for the ALETTA pivotal study across 20 European research sites in five countries, with enrolment positioned to commence in the foreseeable future pending completion of financing arrangements—a critical milestone toward regulatory approval in Europe.
www.arlettapharmasolutions.com
#pharma
#pharmainnovation
#pharmatech
#biotech
